British Journal of Cancer - Table of Contents alert Volume 113 Issue S1

If you are unable to see the message below, click here to view.

PARP inhibitors in ovarian cancer Organizer: AstraZeneca UK Guest Editor: Jonathan A Ledermann In this supplement, the authors comprehensively review molecular and clinical evidence underlying the evolution of poly (ADP-ribose) polymerase (PARP) inhibitors in a journey spanning 50 years, which culminates in the recent licensing approval of the first oral PARP inhibitor, olaparib (Lynparzat™), for BRCA-mutated high-grade serous ovarian cancer. In addition, it discusses current UK procedures for BRCA testing of at-risk women and considers BRCA mutation genetic testing models for patients with ovarian cancer. TABLE OF CONTENTS Volume 113, Issue S1 (S1-S21) Published online 15 December 2015 In this issue Foreword Minireviews Also new today Advance online publication Digital Edition Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement Introducing THE DARWIN CANCER BLOG - "keeping an evolutionary eye on cancer" led by Prof. Mel Greaves and brought to you by BJC. This blog provides a forum for discussing how an evolutionary perspective is changing thinking about cancer and aims to encourage discussion and debate among specialists and general interest readers. >> Start reading the latest content Foreword Top PARP inhibitors in ovarian cancer David Cibula and Judith Balmaña Br J Cancer 2015 113: S1-S2; 10.1038/bjc.2015.392 Full Text | PDF Minireviews Top The development of PARP inhibitors in ovarian cancer: from bench to bedside Yvette Drew Br J Cancer 2015 113: S3-S9; 10.1038/bjc.2015.394 Abstract | Full Text PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions Jonathan A Ledermann and Fatima El-Khouly Br J Cancer 2015 113: S10-S16; 10.1038/bjc.2015.395 Abstract | Full Text UK BRCA mutation testing in patients with ovarian cancer Angela George Br J Cancer 2015 113: S17-S21; 10.1038/bjc.2015.396 Abstract | Full Text Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.